Citations

Clear

4610 citation(s) found for "Lu, Brian".

Variability of inter‐observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma ( RCC ): independent analysis from a phase
Devine, Catherine , Fellman, Bryan , Urbauer, Diana L. , Abel, E. Jason , Bex, Axel , Lane, Brian R. , Thompson, R. Houston, Wood, Christopher G. , Karam, Jose Antonio , Allaf, Mohamad E

Mayo Clinic

BJU International | June 1, 2015 | Volume: 117 | Issue: 4 | Pages: 629-635

10.1111/bju.13188 | PMID 26033220 Get It

Objective To evaluate how many patients could have undergone partial nephrectomy ( PN ) rather than radical nephrectomy ( RN ) before and after neoadjuvant axitinib therapy, as assessed by five independent urological oncologists, and to study the variability of inter‐observer agreement. Patients and Methods Pre‐ and post‐systemic treatment computed tomography scans from 22 patients with clear cell renal cell carcinoma in a phase II neoadjuvant axitinib trial were reviewed by five independent urological oncologists. R.E.N.A.L. nephrometry score and κ statistics were calculated. Results The median R.E.N.A.L. nephrometry score changed from 11 before treatment to 10 after treatment ( P = 0.002). Five tumours with moderate complexity before axitinib treatment remained moderate complexity after treatment. Of 17 tumours with high complexity before axitinib treatment, three became moderate complexity after treatment. The overall κ statistic was 0.611. Moderate‐complexity κ was 0.611 vs a high‐complexity κ of 0.428. Before axitinib treatment the κ was 0.550 vs 0.609 after treatment. After treatment with axitinib, all five reviewers agreed that only five patients required RN (instead of eight before treatment) and that 10 patients could now undergo PN (instead of three before treatment). The odds of PN feasibility were 22.8‐times higher after treatment with axitinib. Conclusions There is considerable variability in inter‐observer agreement on the feasibility of PN in patients treated with neoadjuvant targeted therapy. Although more patients were candidates for PN after neoadjuvant axitinib therapy, it remains difficult to identify these patients a priori .
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Braggio, Esteban , Wier, Scott Van, Ojha, Juhi, McPhail, Ellen D. , Asmann, Yan W. , Egan, Jan B. , Ayres-Silva, Jackline de Paula , Schiff, David , Lopes, M. Beatriz S. , Decker, Paul A. , Valdez, Riccardo, Tibes, Raoul , Eckloff, Bruce W., Stewart, A. Keith, Van Wier, Scott, McPhail, Ellen, Egan, Jan, Eckloff, Bruce, O'Neill, Brian Patrick, McPhail, Ellen Darcy , Decker, Paul A. , Witzig, Thomas E. , Fonseca, Rafaël , O’Neill, Brian Patrick , Braggio, Esteban

Mayo Clinic

Clinical Cancer Research | May 19, 2015 | Volume: 21 | Issue: 17 | Pages: 3986-3994

10.1158/1078-0432.ccr-14-2116 | PMID 25991819 Get It

Abstract Purpose: Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the central nervous system. Whether there is a PCNSL-specific genomic signature and, if so, how it differs from systemic diffuse large B-cell lymphoma (DLBCL) is uncertain. Experimental Design: We performed a comprehensive genomic study of tumor samples from 19 immunocompetent PCNSL patients. Testing comprised array-comparative genomic hybridization and whole exome sequencing. Results: Biallelic inactivation of TOX and PRKCD was recurrently found in PCNSL but not in systemic DLBCL, suggesting a specific role in PCNSL pathogenesis. In addition, we found a high prevalence of MYD88 mutations (79%) and CDKN2A biallelic loss (60%). Several genes recurrently affected in PCNSL were common with systemic DLBCL, including loss of TNFAIP3, PRDM1, GNA13, TMEM30A, TBL1XR1, B2M, CD58, activating mutations of CD79B, CARD11, and translocations IgH-BCL6. Overall, B-cell receptor/Toll-like receptor/NF-κB pathways were altered in >90% of PNCSL, highlighting its value for targeted therapeutic approaches. Furthermore, integrated analysis showed enrichment of pathways associated with immune response, proliferation, apoptosis, and lymphocyte differentiation. Conclusions: In summary, genome-wide analysis uncovered novel recurrent alterations, including TOX and PRKCD, helping to differentiate PCNSL from systemic DLBCL and related lymphomas. Clin Cancer Res; 21(17); 3986–94. ©2015 AACR.
Inverting papilloma of the temporal bone: Report of four new cases and systematic review of the literature
Carlson, Matthew L. , Sweeney, Alex D. , Modest, Mara C., Haynes, David S. , Neff, Brian A., Van Gompel, Jamie J, Gompel, Jamie J. Van

Mayo Clinic

The Laryngoscope | May 9, 2015 | Volume: 125 | Issue: 11 | Pages: 2576-2583

10.1002/lary.25359 | PMID 25959041 Get It

Objectives/HypothesisInverting papillomas (IPs) are benign locally invasive tumors that most commonly present within the sinonasal cavity. Temporal bone involvement is exceedingly rare, with fewer than 30 cases reported within the English literature to date.Study DesignCase series and systematic review of the literature.MethodsFour consecutive subjects with temporal bone inverting papilloma (TBIP) were treated, and an additional 28 previously published cases were identified in the literature. Main outcome measures were disease presentation, diagnostic evaluation, management strategy, and outcome.ResultsA total of 32 cases were analyzed. The median age at diagnosis was 54 years (mean 54.1; range 19–81 years). Nineteen (59%) patients had synchronous or metachronous sinonasal IP, whereas 13 (41%) had isolated temporal bone disease without sinus involvement. Over half of the patients undergoing microsurgical resection experienced at least one recurrence. Compared to patients with a history of sinus IP, subjects with primary TBIP were younger at time of presentation (44 vs. 58 years; P = 0.012); were more commonly female (62% vs. 32%; P = 0.15); and were less likely to have intracranial spread (8% vs. 26%; P = 0.36), cranial neuropathy (8% vs. 26%; P = 0.36), human papillomavirus positivity (11% vs. 57%; P = 0.11), or associated carcinoma (0% vs. 47%; P = 0.004).ConclusionsInverting papilloma of the lateral skull base is rare and can pose a significant therapeutic challenge. Primary lesions of the temporal bone appear to follow a less aggressive clinical course when compared to those arising in association with sinonasal disease. Gross total resection is the preferred method of treatment, when feasible, given the high rate of recurrence with subtotal resection and risk of associated malignancy.Level of Evidence4. Laryngoscope, 125:2576–2583, 2015
TERT gene harbors multiple variants associated with pancreatic cancer susceptibility
Campa, Daniele , Rizzato, Cosmeri , Pacetti, Paola, Vodička, Pavel , Cleary, Sean P. , Capurso, Gabriele , Bueno‐de‐Mesquita, H. Bas, Werner, Jens , Butterbach, Katja, Ivanauskas, Audrius , Giese, Nathalia A. , Petersen, Gloria M. , Fogar, Paola, Bassi, Claudio , Ryska, Miroslav , Theodoropoulos, George , Li, Donghui , Greenhalf, William , Pasquali, Claudio , Hackert, Thilo , Fuchs, Charles S. , Mohelníková-Duchoňová, Beatrice , Funel, Niccola , Dieffenbach, Aida Karina, Buring, Julie E. , Holcátová, Ivana , Costello, Eithne , Zambon, Carlo‐Federico , Kupčinskas, Juozas , Bracci, Paige M. , Pezzilli, Raffaele , Olson, Sara H. , Sesso, Howard D. , Hartge, Patricia, Strobel, Oliver , Małecka‐Panas, Ewa , Visvanathan, Kala , Arslan, Alan A. , Pedrazzoli, Sergio , Souček, Pavel , Gioffreda, Domenica , Talar‐Wojnarowska, Renata , Scarpa, Aldo , Mambrini, Andrea , Jacobs, Eric J. , Jamroziak, Krzysztof , Tavano, Francesca , Bambi, Franco , Landi, Stefano , Austin, Melissa A. , Vodičková, Ludmila, Brenner, Hermann , Fave, Gianfranco Delle, Piepoli, Ada, Cantore, Maurizio , Zheng, Wei , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Canzian, Federico , Wang, Zhaoming , Salvia, Roberto , Stolzenberg‐Solomon, Rachael Z. , Gazouli, Maria , Wang, Zhaoming , Kooperberg, Charles , Sperti, Cosimo , Wareham, Nicholas J. , Kupcinskas, Juozas , Risch, Harvey A. , Kraft, Peter , Key, Tim , Klein, Alison P. , Chanock, Stephen Jacob , Amundadottir, Laufey , Arslan, Alan A , Canzian, Federico , Wang, Zhaoming , Visvanathan, Kala , Brenner, Hermann , Strobel, Oliver , Zheng, Wei , Cleary, Sean P , Vodicka, Pavel , Landi, Stefano , Holcatova, Ivana , Tavano, Francesca

Mayo Clinic

International Journal of Cancer | May 5, 2015 | Volume: 137 | Issue: 9 | Pages: 2175-2183

10.1002/ijc.29590 | PMID 25940397 Get It

A small number of common susceptibility loci have been identified for pancreatic cancer, one of which is marked by rs401681 in the TERT–CLPTM1L gene region on chromosome 5p15.33. Because this region is characterized by low linkage disequilibrium, we sought to identify whether additional single nucleotide polymorphisms (SNPs) could be related to pancreatic cancer risk, independently of rs401681. We performed an in‐depth analysis of genetic variability of the telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC) genes, in 5,550 subjects with pancreatic cancer and 7,585 controls from the PANcreatic Disease ReseArch (PANDoRA) and the PanScan consortia. We identified a significant association between a variant in TERT and pancreatic cancer risk (rs2853677, odds ratio = 0.85; 95% confidence interval = 0.80–0.90, p = 8.3 × 10−8). Additional analysis adjusting rs2853677 for rs401681 indicated that the two SNPs are independently associated with pancreatic cancer risk, as suggested by the low linkage disequilibrium between them (r2 = 0.07, D′ = 0.28). Three additional SNPs in TERT reached statistical significance after correction for multiple testing: rs2736100 (p = 3.0 × 10−5), rs4583925 (p = 4.0 × 10−5) and rs2735948 (p = 5.0 × 10−5). In conclusion, we confirmed that the TERT locus is associated with pancreatic cancer risk, possibly through several independent variants.
Abstract 5585: Integrated DNA/RNA sequencing for discovery and orthogonal validation of expressed fusion genes in peripheral T-cell lymphomas
Vasmatzis, George , Asmann, Yan W. , Johnson, Sarah H. , Eckloff, Bruce W., Kurtin, Paul J. , Ansell, Stephen M. , Feldman, Andrew L. , Middha, Sumit , Davila, Jaime , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 5585-5585

10.1158/1538-7445.am2014-5585 Get It

Abstract Background: Fusion genes, transcripts, and proteins are key drivers of hematopoietic oncogenesis and can serve as effective therapeutic targets. Among peripheral T-cell lymphomas (PTCLs), little is known about fusion genes except for those involving ALK. Discovery of fusion genes may provide therapeutic targets for PTCLs, which have poor outcomes with conventional therapy. We have developed methods for detecting candidate fusions using (1) mate-pair DNA sequencing (MPseq), an approach that spans the entire genome at a fraction of the cost of traditional whole-genome sequencing, and (2) RNA sequencing (RNAseq). Each technique has strengths, limitations, and false discovery rates. Here, we integrated results of both methods to discover and orthogonally validate expressed fusion genes in PTCLs. Methods: DNA and RNA were extracted from 49 frozen, OCT-embedded clinical PTCL specimens, including 25 anaplastic large cell lymphomas; 16 PTCLs, not otherwise specified; and 8 other PTCLs. MPseq and RNAseq were performed using Illumina library protocols and a HiSeq 2000. Detection of fusion genes and transcripts followed our published methods (Blood 2012;120:2280 and Nucleic Acids Res 2011;39:e100, respectively). Functional annotation of genes involved in fusions was performed using DAVID. Results: Of 2818 candidate chromosomal rearrangements identified by MPseq and 90 candidate fusion transcripts identified by RNAseq, 45 events were present in both datasets (mean/case, 0.9; range, 0-7). Fusions were inter-chromosomal in 16 and intra-chromosomal in 29. Annotation clusters with the highest enrichment scores related to SH2 domain-containing proteins and tyrosine kinases (including FER and MAP2K3). Seven genes were recurrently involved in fusions, including known fusion partners such as ALK and previously unreported fusion partners such as PPP1R8, a phosphatase inhibitor important for the activity of Polycomb group proteins such as EZH2. Detection of candidate events only by MPseq could be explained in part by breakpoints mapping to non-genic regions (79% of events). Detection only by RNAseq could be explained in part by unannotated transcripts spanning neighboring named genes (median intra-chromosomal distance, 0.09 MB vs. 12.7 MB for intra-chromosomal candidates identified by MPseq; p<0.0001, Wilcoxon test). Conclusions: Integrated DNA/RNA sequencing is an effective, clinically feasible tool for simultaneous discovery and orthogonal validation of expressed fusion genes. This approach yielded fusions in PTCLs involving genes with key functions in lymphocytes, including novel and recurrent fusions, some of which might be targetable with compounds currently in clinical trial. Candidate intra-chromosomal fusion transcripts not identified by MPseq may represent unrecognized isoforms or the results of novel read-through mechanisms, and merit further study. Citation Format: Andrew L. Feldman, George Vasmatzis, Yan W. Asmann, Sarah H. Johnson, Bruce W. Eckloff, Sumit Middha, Jaime I. Davila, Paul J. Kurtin, Brian K. Link, Stephen M. Ansell, James R. Cerhan. Integrated DNA/RNA sequencing for discovery and orthogonal validation of expressed fusion genes in peripheral T-cell lymphomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5585. doi:10.1158/1538-7445.AM2014-5585
Abstract 4297: Quantifying three-dimensional cellular morphology and its heterogeneity in epithelial cancers by single-cell optical tomography
Nandakumar, Vivek , Helland, Stephanie, Han, Jessica H., Davis, Geriann, Ashcroft, Brian , Tran, Thai H., Li, Ting , Anderson, Karen S. , Pannala, Rahul , Fleischer, David E., Johnson, Roger H., Meldrum, Deirdre R., Mıkhael, Joseph , Bussey, Kimberly J.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 4297-4297

10.1158/1538-7445.am2014-4297 Get It

Abstract The three-dimensional (3D) structure of the cell and its nucleus is intricately associated with cellular function. Aberrations and heterogeneity in cellular and nuclear morphology serve as diagnostically important cues to identify malignant transformation. However, current cytopathology practice is predominantly based on a qualitative, 2D assessment of cellular morphology that may bias the diagnosis. We utilized the Cell-CT® platform to perform single-cell, optical tomography imaging and generate 3D cell images with isotropic, sub-micron spatial resolution. We developed custom image analysis tools to accurately quantify 3D cell and nuclear morphology. We used these measures to characterize the morphological heterogeneity within and among epithelial cell populations, and to identify morphological descriptors that are reliably predictive of cell state. We assessed the efficacy of our approach relative to conventional 2D assessment (at 40x magnification) to detect malignant transformation in immortalized and primary normal-cancer cell line pairs from human esophagus and breast epithelia. We observed the 3D method of assessment to provide a consistently superior performance (sensitivity and specificity) in predicting malignant transformation. Further, some widely used diagnostic parameters, such as nuclear size or nucleus-to-cytoplasm ratio, did not always exhibit the highest predictive power in 3D space. The availability of 3D morphological information also provided novel insights on intra-population morphological heterogeneity in both normal and cancer cell populations. Our results emphasize the need to incorporate 3D morphological information into standard pathological practice. Citation Format: Vivek Nandakumar, Stephanie Helland, Jessica H. Han, Geriann Davis, Brian A. Ashcroft, Thai H. Tran, Ting Li, Karen S. Anderson, Rahul Pannala, Joseph R. Mikhael, David E. Fleischer, Roger H. Johnson, Kimberly J. Bussey, Deirdre R. Meldrum. Quantifying three-dimensional cellular morphology and its heterogeneity in epithelial cancers by single-cell optical tomography. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4297. doi:10.1158/1538-7445.AM2014-4297
Abstract 1894: Extensive genomic profiling of a rare extranodal-follicular dendritic cell sarcoma: Implications for future individualized therapy
Starr, Jason S. , Attia, Steven , Wang, Xue , Necela, Brian M. , John, Casler, Menke, David M. , Sarangi, Vivek, Copland, John A. , Parker, Alexander A., Thompson, E. Aubrey, Smallridge, Robert C., Asmann, Yan W. , Davila, Jaime , Wang, Chen , Oliver, Gavin R. , Joseph, Richard W. , Parker, Alexander

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 1894-1894

10.1158/1538-7445.am2014-1894 Get It

Abstract Background: Extranodal follicular dendritic cell sarcoma (FDCS) is an exceedingly rare tumor type that is limited to few cases in the literature. Given the rarity of this tumor, there is a lack of genetic understanding of this disease resulting in a non-individualized plan of care for patients with this disease. Herein, we are the first to describe extensively molecularly the DNA and RNA of this tumor. Methods: Under an IRB approved protocol, the patient's tumor and whole blood was freshly frozen for molecular analysis. We performed Next Generation Sequencing (NGS) genomic profiling including exome capture, mate pair and mRNA sequencing on this tumor. Exome and mRNA data were processed through Mayo's Bioinformatics Core standard pipelines, GENOME GPS 1.2.1 and MAPRSeq v1.2.1. Mutations and indels were prioritized depending on whether or not they belonged to known cancer associated genes. Copy number variations (CNVs) in Exome and Mate Pair data was found through PatternCNV v 1.0.1 and fusion transcripts were found using SNOWSHOES-FTD and Tophat-Fusion 2.0.6. Results: At the genomic level large scale genomic rearrangements were detected, including chr19 and chr20 trisomy, chr15q and chr17q segmental duplications result in two intra-chromosomal fusion genes, and translocations leading to four inter-chromosomal fusion genes between chr15 and chr17. Of particular interest is a stop codon gain in the CLTC1 (chr22) gene, which is involved in the mitotic spindle organization which has been associated with meningiomas and breast tumorigenesis. The new stop codon is before the site required for the recruitment of the proteins to the spindle. The large scale genomic rearrangement described above is consistent with this defective spindle assembly hypothesis. Another intriguing mutation detected in the VEGFR1 (chr13) gene leads to a 45% mis-spliced transcript. VEGFR1 is thought to modulate VEGFR2 which plays an essential role in angiogenesis, by acting as a decoy receptor. Therefore the loss of function of VEGFR1 might lead to hyper-activity of VEGFR2 pathway and a potential therapeutic strategy is to directly inhibit the VEGFR2 pathway. Furthermore missense mutations in the ATM (chr11) and TP53 (chr17) genes were found. PARP inhibitors have been used with success for cancer with defects in the ATM gene. Finally a novel fusion transcript of HDGRFP3 (chr15) and SHC4 (chr15) was identified. Such fusion results in an overexpressed SHC4 gene which has been associated with metastatic melanomas. Conclusions: In summary, genomic profiling of a rare thyroid FDCS identified drug targetable genes as well as changes related to tumor etiology. Future work is necessary to determine the functional significance of these molecular findings and whether they will predict benefit to targeted therapies. Citation Format: Jaime I. Davila, Jason Starr, Steven Attia, Chen Wang, Xue Wang, Brian Necela, Casler John, David Menke, Vivek Sarangi, Gavin Oliver, Richard Joseph, John Copland, Alexander Parker, E. Aubrey Thompson, Robert Smallridge, Yan W. Asmann. Extensive genomic profiling of a rare extranodal-follicular dendritic cell sarcoma: Implications for future individualized therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1894. doi:10.1158/1538-7445.AM2014-1894
Abstract P6-07-03: An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Feldman, Andrew L. , Cerhan, James R.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: P6-07-03-P6-07-03

10.1158/1538-7445.sabcs14-p6-07-03 Get It

Abstract Objectives and Rationale: Structural variants (SV) including large copy number aberrations (CNV), translocations, inversions, and large insertions and deletions (INDEL) play a critical role in tumorigenesis and progression. In fact, we now know that tumors can be categorized according to the size of mutations harbored. In several cancers, including ovarian and breast cancer, the large structural mutations, rather than single site mutations, play a dominate role in tumor etiology. Therefore, it's critical to implement reliable algorithm for the detection of structural variants in DNA sequencing data. Mate-pair sequencing is a protocol specifically implemented for detection of the whole-genome level structural variants. It requires less sequencing depth therefor is cost effective, and enables the detection of CNVs, translocations, and inversions simultaneously. However, so far there has been no reliable bioinformatics pipeline for the analyses of the mate-pair sequencing data. Methods: Our novel algorithm, the SnowShoes-SV, is an exhaustive search algorithm designed specifically for mate-pair DNA sequencing data analyses. It calls the SVs based on disconcordant read pairs. The false SVs are filtered according to the following criteria: (i) the number of the supporting read pairs; (ii) the lack of reads from control data that implicate SV at the same region; (iii) the mappability and uniqueness of the region based on data from the ENCODE project; (iv) consistencies of the mapping orientations of the supporting read pairs; (v) the similar sizes between sequencing library and the two end read clusters. Results: Using a set of samples previously genotyped by aCGH, the SnowShoes-SV successfully detected all known CNVs and other SVs. It also identified copy number neutral translocations and inversions previously not identified by aCGH. In addition, the algorithm nominated novel SVs which are to be validated by PCR. Conclusions: SnowShoes-SV is a highly sensitive and specific algorithm for SV detection from the mate-pair DNA sequencing data. Citation Format: Yan W Asmann, Chen Wang, Brian M Necela, Xianfeng Chen, Jean-Pierre A Kocher, Matthew J Maurer, Thomas M Habermann, Susan L Slager, Andrew L Feldman, Anne J Novak, James R Cerhan, Edith A Perez, E Aubrey Thompson. An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-07-03.
Abstract LB-282: Transethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A
Wang, Hansong, Burnett, Terrilea, Kono, Suminori , Haiman, Christopher, Loo, Lenora W. M. , Kolonel, Laurence, Henderson, Brian E., Signorello, Lisa B., Blot, William J. , West, Dee W., Bezieau, Stéphane , Berndt, Sonja I. , Zanke, Brent W., Lindor, Noralane M. , Jenkins, Mark A. , Gallinger, Steven , Casey, Graham , Stenzel, Stephanie L., Peters, Ulrike , Gruber, Stephen B. , Stram, D. O., Iwasaki, Motoki , Wilkens, Lynne R. , Berg, David Van Den , Keku, Temitope O , Sandler, Robert S. , Newcomb, Polly A. , Pande, Mala , Amos, Christopher I. , Hsu, Li , Haile, Robert W. , Hopper, John L. , Schumacher, Fredrick R. , Tsugane, Shoichiro , Marchand, Loı̈c Le , Jenkins, Mark A , Bézieau, Stéphane

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: LB-282-LB-282

10.1158/1538-7445.am2014-lb-282 Get It

Abstract To identify genetic variants that contribute to colorectal cancer (CRC) susceptibility, we performed a meta-analysis of two genome-wide association studies in 2,627 cases and 3,797 controls of Japanese ancestry and 1,894 cases and 4,703 controls of African ancestry, followed by a replication of genome-wide statistically significant associations (P < 5E-8) in 16,823 cases and 18,211 controls of European ancestry. This study revealed a new pan-ethnic CRC risk locus at 10q25 (rs12241008, intronic to VTI1A; P=1.5E-9), providing additional insight into the etiology of CRC and highlighting the value of association mapping in diverse populations. Citation Format: Hansong Wang, Terrilea Burnett, Suminori Kono, Christopher Haiman, Motoki Iwasaki, Lynne Wilkens, Lenora Loo, David Van Den Berg, Laurence Kolonel, Brian Henderson, Temitope Keku, Robert Sandler, Lisa Signorello, William Blot, Polly Newcomb, Mala Pande, Christopher Amos, Dee West, Stéphane Bézieau, Sonja Berndt, Brent Zanke, Li Hsu, Noralane Lindor, Robert Haile, John Hopper, Mark Jenkins, Steven Gallinger, Graham Casey, Stephanie Stenzel, Fredrick Schumacher, Ulrike Peters, Stephen Gruber, Shoichiro Tsugane, Dan Stram, Loic Le Marchand. Transethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-282. doi:10.1158/1538-7445.AM2014-LB-282
Abstract 4714: The association of glioma germline risk SNPs with mutation-based molecular subgroups
Eckel‐Passow, Jeanette E. , Kollmeyer, Thomas M. , Sarkar, Gobinda , Chada, Anisha R. , Decker, Paul A. , Kosel, Matthew , Caron, Alissa, Sicotte, Hugues , Nandakumar, Kannabiran, Prodduturi, Naresh, Jenkins, Robert B. , Decker, Paul A. , O’Neill, Brian Patrick , Lachance, Daniel Honore , Kollmeyer, Thomas

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 4714-4714

10.1158/1538-7445.am2014-4714 Get It

Abstract Background: Specific germline alterations within the TERT, EGFR, CCDC26, CDKN2A/B, PHLDB1, TP53 and RTEL1 regions are associated with development of glioma. While some of these germline variants are associated with all gliomas (e.g. rs2736100 in TERT), others are associated with a specific morphologic and/or molecular subtype. For example, the RTEL1 region variants are associated with primary glioblastoma and rs55705857 in CCDC26 is associated with 1p/19q co-deleted oligodendrogliomas and with IDH mutant astrocytic gliomas. We hypothesized that germline variants in these regions will be associated with other molecular subtypes. The Cancer Genome Atlas (TCGA) and other groups have described molecular subtypes of glioma based on acquired somatic mutation patterns. Herein, we grouped glioma patients into mutation-based molecular subgroups based on three molecular alterations and determined if germline polymorphisms are associated with these mutation-based molecular subtypes. Methods: Five molecular subtypes were defined based on combinations of the following molecular alterations: TERT promoter mutation (TERTmut vs. TERTwt), IDH1/2 mutation (IDH mut vs. IDH wt) and 1p/19q co-deletion (1p19qcodel vs. 1p19q noncodel). Germline single nucleotide polymorphisms (SNPs) were evaluated by custom Illumina array analysis of blood-derived DNA and 1K genome imputation. Results: One hundred ninety-nine gliomas (24 oligodendrogliomas, 59 mixed oligoastrocytomas, 41 grade 2-3 astrocytomas and 75 glioblastomas) had both SNP data and mutation data available in order to assign them into the five molecular subgroups. The prevalence of each of the molecular subtypes was as follows: TERTmut/IDHmut/1p19qcodel (20%), TERTmut/IDHmut/1p19qnoncodel (5%), TERTmut/IDHwt/1p19qnoncodel (32%), TERTwt/IDHmut/1p19qnondel (35%) and TERTwt/IDHwt/1p19qnoncodel (8%). The TERT SNP (rs2736100) was protective for TERTmut/IDHmut/1p19qnoncodel and TERTwt/IDHmut/1p19qnoncodel gliomas. The CCDC26 SNP (rs55705857) was strongly associated with the risk of developing TERTmut/IDHmut/1p19qcodel and TERTwt/IDHmut/1p19qnoncodel gliomas. The TP53 SNP (rs7837822) was strongly associated with risk of developing TERTmut/IDHmut/1p19qnoncodel and TERTwt/IDHmut/1p19qnoncodel gliomas. Interestingly, while one RTEL1 region SNP (rs6062297) was strongly associated with glioma risk, RTEL1 SNPs rs6010620 and rs2297440 were protective for the development of TERTmut/IDHwt/1p19qnoncodel gliomas. We are currently in the process of validating these results using the TCGA glioblastoma and low grade glioma data. Conclusions: Glioma patients can be meaningfully classified according to their acquired mutation subtype. Importantly, our results suggest that there are significant associations between germline polymorphisms and mutation-based glioma molecular subtypes. Citation Format: Jeanette E. Eckel-Passow, Thomas M. Kollmeyer, Gobinda Sarkar, Anisha Chada, Paul A. Decker, Matthew L. Kosel, Alissa A. Caron, Hugues Sicotte, Kannabiran Nandakumar, Naresh Prodduturi, Brian P. O'Neill, Daniel H. Lachance, Robert B. Jenkins. The association of glioma germline risk SNPs with mutation-based molecular subgroups. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4714. doi:10.1158/1538-7445.AM2014-4714